Jump to content

Fletikumab

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 04:16, 4 October 2021 (Add: doi-access. | Use this bot. Report bugs. | Suggested by Headbomb | Linked from Wikipedia:WikiProject_Academic_Journals/Journals_cited_by_Wikipedia/Sandbox | #UCB_webform_linked 53/1128). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Fletikumab
Monoclonal antibody
Type?
TargetIL20
Clinical data
Other namesNNC0109-0012
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC6494H10000N1728O2050S44
Molar mass146492.12 g·mol−1

Fletikumab (NNC0109-0012) (INN[1]) is a monoclonal antibody designed for the treatment of rheumatoid arthritis[2] that targets IL-20.[3]

This drug was being developed by Novo Nordisk A/S until Novo ceased work in inflammation.

References

  1. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Fletikumab, American Medical Association.
  3. ^ Kragstrup TW, Andersen T, Heftdal LD, Hvid M, Gerwien J, Sivakumar P, Taylor PC, Senolt L, Deleuran B (2018). "The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis". Frontiers in Immunology. 9: 2226. doi:10.3389/fimmu.2018.02226. PMC 6167463. PMID 30319661.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Fletikumab&oldid=1048080705"